Jing Jie Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jing Jie Yu has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Yi Guo
University of Maryland Shore Regional Health, Easton, MD, U.S.A.
6 shared publicationsXiaobing Liang
Department of Biochemistry, School of Medicine, School of Pharmacy, WVU Cancer Institute, Morgantown, WV, U.S.A.
5 shared publicationsXuqing Yang
College of Chemistry and Molecular Engineering, Peking University, Beijing, P.R. China
4 shared publications- Eddie Reed
National Institutes of Health, Bethesda, MD, U.S.A.
3 shared publications Honglan Zhu
3 shared publicationsMichael D. Mueller
3 shared publications
Latest Publications
- Open Access
- 29 November 2025
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 45 (12) , 5247-5254
Dicycloplatin, a Novel Analog of Cisplatin and Carboplatin, May Provide Therapeutic Advancement in Cancer Chemotherapy
Platinum-based chemotherapeutic agents have been the cornerstone in cancer treatment for decades. However, their clinical utility is often limited by severe adverse effects and the development of drug resistance. Dicycloplatin (DCP), a novel platinum analog developed in China, has emerged as a promising alternative with potentially improved therapeutic profiles. This review examines the development, pharmacology, molecular mechanism, and clinical applications of DCP in various cancer types. Available evidence suggests that DCP maintains similar efficacy to conventional platinum compounds while demonstrating reduced toxicity. Both intravenous and oral formulations have shown promising results, particularly in bladder cancer, lung cancer, and hepatocellular carcinoma. The first American bladder cancer patient treated with DCP achieved complete remission twice. The first achievement for the bladder primary tumor was in 2016 by 8-weeks IV DCP chemotherapy. The second complete remission of tumor recurrence was in 2021 after 7-weeks oral DCP therapy. This case highlights DCP potential clinical value. This review also discusses ongoing research, regulatory status, and future directions for DCP in cancer chemotherapy. While more extensive clinical trials are needed, particularly in Western populations. Current data suggest that DCP may represent a significant advancement in platinum-based chemotherapy, potentially offering improved quality of life for cancer patients without compromising treatment efficacy.
- 29 November 2025
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 45 (12) , 5247-5254
Open AccessDicycloplatin, a Novel Analog of Cisplatin and Carboplatin, May Provide Therapeutic Advancement in Cancer Chemotherapy
Platinum-based chemotherapeutic agents have been the cornerstone in cancer treatment for decades. However, their clinical utility is often limited by severe adverse effects and the development of drug resistance. Dicycloplatin (DCP), a novel platinum analog developed in China, has emerged as a promising alternative with potentially improved therapeutic profiles. This review examines the development, pharmacology, molecular mechanism, and clinical applications of DCP in various cancer types. Available evidence suggests that DCP maintains similar efficacy to conventional platinum compounds while demonstrating reduced toxicity. Both intravenous and oral formulations have shown promising results, particularly in bladder cancer, lung cancer, and hepatocellular carcinoma. The first American bladder cancer patient treated with DCP achieved complete remission twice. The first achievement for the bladder primary tumor was in 2016 by 8-weeks IV DCP chemotherapy. The second complete remission of tumor recurrence was in 2021 after 7-weeks oral DCP therapy. This case highlights DCP potential clinical value. This review also discusses ongoing research, regulatory status, and future directions for DCP in cancer chemotherapy. While more extensive clinical trials are needed, particularly in Western populations. Current data suggest that DCP may represent a significant advancement in platinum-based chemotherapy, potentially offering improved quality of life for cancer patients without compromising treatment efficacy.
- Open Access
- 26 February 2022
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 42 (3) , 1339-1344
First American Cancer Patient to Receive Dicycloplatin (DCP) Chemotherapy Achieves Remission After Seven Weeks of DCP Capsules – A Case Report
Background: The majority of bladder cancer patients experience recurrence. Cisplatin is the standard chemotherapy for muscle-invasive bladder cancer though adverse effects are often severe. Case Report: Intravenous (IV) dicycloplatin (DCP) sustained remission in an American bladder cancer patient for five years. A recurrent mass was observed in July 2021. The patient received DCP capsules for seven weeks with no significant side-effects. Complete blood count with differential and a basic metabolic panel showed no adverse effects of DCP capsules on the bone marrow, liver or renal parameters. Cystoscopy after oral DCP found no evident bladder tumors; cytology was negative for high-grade urothelial carcinoma. Conclusion: In this patient, DCP-capsules appeared to be as effective as DCP-IV for achieving bladder cancer remission. Both forms of DCP chemotherapy are convenient, active against several cancer types, with decreased adverse effects compared to cisplatin. Both have been available for treating cancer patients in China. A USA clinical trial of DCP in bladder and other cancers appears warranted.
- 26 February 2022
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 42 (3) , 1339-1344
Open AccessFirst American Cancer Patient to Receive Dicycloplatin (DCP) Chemotherapy Achieves Remission After Seven Weeks of DCP Capsules – A Case Report
Background: The majority of bladder cancer patients experience recurrence. Cisplatin is the standard chemotherapy for muscle-invasive bladder cancer though adverse effects are often severe. Case Report: Intravenous (IV) dicycloplatin (DCP) sustained remission in an American bladder cancer patient for five years. A recurrent mass was observed in July 2021. The patient received DCP capsules for seven weeks with no significant side-effects. Complete blood count with differential and a basic metabolic panel showed no adverse effects of DCP capsules on the bone marrow, liver or renal parameters. Cystoscopy after oral DCP found no evident bladder tumors; cytology was negative for high-grade urothelial carcinoma. Conclusion: In this patient, DCP-capsules appeared to be as effective as DCP-IV for achieving bladder cancer remission. Both forms of DCP chemotherapy are convenient, active against several cancer types, with decreased adverse effects compared to cisplatin. Both have been available for treating cancer patients in China. A USA clinical trial of DCP in bladder and other cancers appears warranted.
- 31 July 2019
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 39 (8) , 4455-4462
Adverse Effects Profile of Dicycloplatin (DCP) Offers Chemotherapeutic Advantage Over Cisplatin and Carboplatin
Background/Aim: Platinum-based chemotherapy often fails due to its severe adverse effects. The aim of this study was to examine the adverse effects profile and efficacy of dicycloplatin and compare them to those of cisplatin and carboplatin. Materials and Methods: Cystoscopy surveillance of the first American cancer patient treated with dicycloplatin was performed quarterly. In vitro and in vivo studies were conducted using immunoblotting and flow cytometry to assess immune status of spleen and bone marrow of mice treated with dicycloplatin, cisplatin and carboplatin. Results: The American patient did not suffer clinically significant myelosuppression; dicycloplatin has sustained remission in this patient to date. Experimental studies showed that dicycloplatin is less toxic to bone marrow and spleen of mice than cisplatin and carboplatin. Conclusion: Dicycloplatin is a promising drug in cancer chemotherapy with less aggressive side-effects than those typically associated with cisplatin and carboplatin. This is an important therapeutic advantage in cancer chemotherapy. Clinical investigation of dicycloplatin as an alternative to cisplatin or carboplatin is warranted.
- 31 July 2019
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 39 (8) , 4455-4462
Adverse Effects Profile of Dicycloplatin (DCP) Offers Chemotherapeutic Advantage Over Cisplatin and Carboplatin
Background/Aim: Platinum-based chemotherapy often fails due to its severe adverse effects. The aim of this study was to examine the adverse effects profile and efficacy of dicycloplatin and compare them to those of cisplatin and carboplatin. Materials and Methods: Cystoscopy surveillance of the first American cancer patient treated with dicycloplatin was performed quarterly. In vitro and in vivo studies were conducted using immunoblotting and flow cytometry to assess immune status of spleen and bone marrow of mice treated with dicycloplatin, cisplatin and carboplatin. Results: The American patient did not suffer clinically significant myelosuppression; dicycloplatin has sustained remission in this patient to date. Experimental studies showed that dicycloplatin is less toxic to bone marrow and spleen of mice than cisplatin and carboplatin. Conclusion: Dicycloplatin is a promising drug in cancer chemotherapy with less aggressive side-effects than those typically associated with cisplatin and carboplatin. This is an important therapeutic advantage in cancer chemotherapy. Clinical investigation of dicycloplatin as an alternative to cisplatin or carboplatin is warranted.
- Open Access
- 17 December 2016
- Published by Graphy Publications in International Journal of Clinical Pharmacology & Pharmacotherapy
- Vol. 1 (2)
DNA Damage Repair and TP53 Gene in Platinum-drug Resistance
Tumor drug resistance remains a major obstacle in the treatment of cancers. Increased DNA repair is a primary mechanism of acquired resistance to platinum chemotherapy. TP53, Chk2 and ERCC1 of the DNA damage/repair pathway were activated after cells were exposed to cisplatin or dicycloplatin. Overexpression of p53 in wt-p53 (but not p53-deficient) cells doubled Chk2 phosphorylation. p53 knockdown greatly reduced Chk2 phosphorylation, indicating that wild type p53, in response to platinum-drugs, plays a role in the upstream regulation of the DNA-adduct repair pathway and mediates acquired platinum resistance. We strongly suggest that it is important to include p53 mutational status in any p53-involved studies due to the functional differentiation of wt-p53 and p53-mutant.
- 17 December 2016
- Published by Graphy Publications in International Journal of Clinical Pharmacology & Pharmacotherapy
- Vol. 1 (2)
Open AccessDNA Damage Repair and TP53 Gene in Platinum-drug Resistance
Tumor drug resistance remains a major obstacle in the treatment of cancers. Increased DNA repair is a primary mechanism of acquired resistance to platinum chemotherapy. TP53, Chk2 and ERCC1 of the DNA damage/repair pathway were activated after cells were exposed to cisplatin or dicycloplatin. Overexpression of p53 in wt-p53 (but not p53-deficient) cells doubled Chk2 phosphorylation. p53 knockdown greatly reduced Chk2 phosphorylation, indicating that wild type p53, in response to platinum-drugs, plays a role in the upstream regulation of the DNA-adduct repair pathway and mediates acquired platinum resistance. We strongly suggest that it is important to include p53 mutational status in any p53-involved studies due to the functional differentiation of wt-p53 and p53-mutant.
- 1 January 2014
- Vol. 34 (1) , 455-63
Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of chinese pre-clinical and clinical profile and emerging mechanistic studies.
Dicycloplatin (DCP) has better solubility and stability than both cisplatin and carboplatin. Pre-clinical and phase I studies demonstrated significant antitumor activity and fewer adverse events than carboplatin. Phase II clinical trials in advanced non-small cell lung cancer found efficacy and safety of DCP-plus-paclitaxel comparable to carboplatin-plus-paclitaxel but better tolerability. This article summarizes and reviews pre-clinical and clinical data for dicycloplatin from the Chinese medical literature. We also report on new mechanistic findings in our laboratory in West Virginia, USA. Patient blood samples were collected for DCP-prototype determination by liquid chromatography mass spectrometry (LC-MS/MS). Molecular studies of ovarian cancer cells treated with DCP or cisplatin were carried out for gene-signature profiling using immunoblotting. Pharmacokinetic mass-spectrometry showed different spectrum profiles of DCP and carboplatin in plasma. Plasma concentration of DCP prototype was 17.1 μg/ml 2h after administration, with a peak concentration of 26.9 μg/ml at 0.5 h. Immunoblotting showed DCP-induced activation of DNA damage pathways, including double-phosphorylated checkpoint kinase 2 (CHK2) and breast cancer 1 (BRCA1) and triple-phosphorylated p53, compared to controls. Cisplatin produced a similar profile, with increased p53 protein. DCP and cisplatin activate DNA-damage response through similar pathways. DCP may be more soluble and stable, and better-tolerated.
- 1 January 2014
- Vol. 34 (1) , 455-63
Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of chinese pre-clinical and clinical profile and emerging mechanistic studies.
Dicycloplatin (DCP) has better solubility and stability than both cisplatin and carboplatin. Pre-clinical and phase I studies demonstrated significant antitumor activity and fewer adverse events than carboplatin. Phase II clinical trials in advanced non-small cell lung cancer found efficacy and safety of DCP-plus-paclitaxel comparable to carboplatin-plus-paclitaxel but better tolerability. This article summarizes and reviews pre-clinical and clinical data for dicycloplatin from the Chinese medical literature. We also report on new mechanistic findings in our laboratory in West Virginia, USA. Patient blood samples were collected for DCP-prototype determination by liquid chromatography mass spectrometry (LC-MS/MS). Molecular studies of ovarian cancer cells treated with DCP or cisplatin were carried out for gene-signature profiling using immunoblotting. Pharmacokinetic mass-spectrometry showed different spectrum profiles of DCP and carboplatin in plasma. Plasma concentration of DCP prototype was 17.1 μg/ml 2h after administration, with a peak concentration of 26.9 μg/ml at 0.5 h. Immunoblotting showed DCP-induced activation of DNA damage pathways, including double-phosphorylated checkpoint kinase 2 (CHK2) and breast cancer 1 (BRCA1) and triple-phosphorylated p53, compared to controls. Cisplatin produced a similar profile, with increased p53 protein. DCP and cisplatin activate DNA-damage response through similar pathways. DCP may be more soluble and stable, and better-tolerated.
- Open Access
- 3 October 2011
- Published by Spandidos Publications in Oncology Reports
- Vol. 27 (1) , 286-292
Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer
The aim of this study was to better understand the mechanisms of tumor development and disease progression in human epithelial ovarian cancer. Fifty genes were screened for gene signature; 20 expressed genes were assessed in tumor and normal samples of EOC patients by RT-PCR. Expression of UBE2I, EGF, TAL2 and ILF3 was validated by qPCR on the ABI Prism 7000 Detection System. ERCC1 and XPB expression was previously determined by RT-PCR in these specimens. Statistical analyses include two-sided Kruskal-Wallis test, pairwise comparison, Pearson correlation coefficient and paired t-test. In comparison to normal samples, 6 genes demonstrated distinct expression patterns in tumor tissues, with high expression observed for ERCC1, XPB and ILF3 (p=0.001, 0.0007 and 0.002, respectively) and low expression observed for TAL2 and EGF (both p<0.0001). This differential expression pattern between normal and tumor tissues may reflect in part the development of ovarian cancer. Significant differences in expression patterns of these genes in clear cell, endometrioid, mucinous and serous ovarian cancer were observed. Comparison of expression of any two EOC subtypes revealed multiple gene involvement in histopathological differentiation and cancer progression. A positive association was found between ERCC1 and XPB expression (r=0.53, p<0.0001) and between TAL2 and EGF expression (r=0.817, p<0.0001) suggesting the existence of gene linkage in these tumors. The differences in expression patterns of studied genes between tumors and normal specimens, between histological subtypes and correlations among studied genes, may indicate their involvement in tumor growth and disease progression in human epithelial ovarian cancer. Further investigation of these genes may enable better understanding of the molecular mechanism of tumorigenesis and identification of potential biomarkers.
- 3 October 2011
- Published by Spandidos Publications in Oncology Reports
- Vol. 27 (1) , 286-292
Open AccessCorrelations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer
The aim of this study was to better understand the mechanisms of tumor development and disease progression in human epithelial ovarian cancer. Fifty genes were screened for gene signature; 20 expressed genes were assessed in tumor and normal samples of EOC patients by RT-PCR. Expression of UBE2I, EGF, TAL2 and ILF3 was validated by qPCR on the ABI Prism 7000 Detection System. ERCC1 and XPB expression was previously determined by RT-PCR in these specimens. Statistical analyses include two-sided Kruskal-Wallis test, pairwise comparison, Pearson correlation coefficient and paired t-test. In comparison to normal samples, 6 genes demonstrated distinct expression patterns in tumor tissues, with high expression observed for ERCC1, XPB and ILF3 (p=0.001, 0.0007 and 0.002, respectively) and low expression observed for TAL2 and EGF (both p<0.0001). This differential expression pattern between normal and tumor tissues may reflect in part the development of ovarian cancer. Significant differences in expression patterns of these genes in clear cell, endometrioid, mucinous and serous ovarian cancer were observed. Comparison of expression of any two EOC subtypes revealed multiple gene involvement in histopathological differentiation and cancer progression. A positive association was found between ERCC1 and XPB expression (r=0.53, p<0.0001) and between TAL2 and EGF expression (r=0.817, p<0.0001) suggesting the existence of gene linkage in these tumors. The differences in expression patterns of studied genes between tumors and normal specimens, between histological subtypes and correlations among studied genes, may indicate their involvement in tumor growth and disease progression in human epithelial ovarian cancer. Further investigation of these genes may enable better understanding of the molecular mechanism of tumorigenesis and identification of potential biomarkers.
- Open Access
- 1 December 2010
- Published by Wiley in Chemotherapy Research and Practice
- Vol. 2011, 1-8
The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor
The major obstacle in platinum chemotherapy is the repair of platinum-damaged DNA that results in increased resistance, reduced apoptosis, and finally treatment failure. Our research goal is to determine and block the mechanisms of platinum resistance. Our recent studies demonstrate that several kinases in the DNA-repair pathway are activated after cells are exposed to cisplatin. These include ATM, p53, and Chk2. The increased Chk2 phosphorylation is modulated by p53 in a wild-type p53 model. Overexpression of p53 by cDNA transfection in wt-p53 (but not p53 deficient) cells doubled the amount of Chk2 phosphorylation 48 hours after cisplatin treatment. p53 knockdown by specific siRNA greatly reduced Chk2 phosphorylation. We conclude that wild-type p53, in response to cisplatin stimulation, plays a role in the upstream regulation of Chk2 phosphorylation at Thr-68. Cells without normal p53 function survive via an alternative pathway in response to the exogenous influence of cisplatin. We strongly suggest that it is very important to include the p53 mutational status in any p53 involved studies due to the functional differentiation of wt p53 and p53 mutant. Inhibition of Chk2 pathway with a Chk2 inhibitor (C3742) increased cisplatin efficacy, especially those with defective p53. Our findings suggest that inhibition of platinum resistance can be achieved with a small-molecule inhibitor of Chk2, thus improving the therapeutic indices for platinum chemotherapy.
- 1 December 2010
- Published by Wiley in Chemotherapy Research and Practice
- Vol. 2011, 1-8
Open AccessThe Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor
The major obstacle in platinum chemotherapy is the repair of platinum-damaged DNA that results in increased resistance, reduced apoptosis, and finally treatment failure. Our research goal is to determine and block the mechanisms of platinum resistance. Our recent studies demonstrate that several kinases in the DNA-repair pathway are activated after cells are exposed to cisplatin. These include ATM, p53, and Chk2. The increased Chk2 phosphorylation is modulated by p53 in a wild-type p53 model. Overexpression of p53 by cDNA transfection in wt-p53 (but not p53 deficient) cells doubled the amount of Chk2 phosphorylation 48 hours after cisplatin treatment. p53 knockdown by specific siRNA greatly reduced Chk2 phosphorylation. We conclude that wild-type p53, in response to cisplatin stimulation, plays a role in the upstream regulation of Chk2 phosphorylation at Thr-68. Cells without normal p53 function survive via an alternative pathway in response to the exogenous influence of cisplatin. We strongly suggest that it is very important to include the p53 mutational status in any p53 involved studies due to the functional differentiation of wt p53 and p53 mutant. Inhibition of Chk2 pathway with a Chk2 inhibitor (C3742) increased cisplatin efficacy, especially those with defective p53. Our findings suggest that inhibition of platinum resistance can be achieved with a small-molecule inhibitor of Chk2, thus improving the therapeutic indices for platinum chemotherapy.
- Open Access
- 17 May 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (5) , e10477
HPV Infection and EGFR Activation/Alteration in HIV-Infected East African Patients with Conjunctival Carcinoma
There has been substantial growth in the numbers of patients with conjunctival squamous cell carcinoma infected with HIV in East Africa. The natural history of the conjunctival squamous cell carcinoma appears to be unique in this region of the world, but the etiologic mechanism unclear and therapeutic options limited. This research was carried out to determine if conjunctival squamous cell carcinoma harbors human papillomavirus DNA and is associated with activation of the EGFR signaling pathway. Positive findings would identify etiologic causes and provide clinical guidance to improve treatment. Expression of p-MAPK/MAPK, p-Akt/Akt and p-EGFR/EGFR in cell nuclei and cytoplasm of 38 FFPE specimens were assessed by immunohistochemistry; HPV genotype was detected by qPCR assay; EGFR mutation was assessed by DNA sequencing analysis; and EGFR mRNA expression was measured using relative qPCR. Statistical analyses included two-sided Fisher exact test or chi-square test, Spearman correlation coefficient and ANOVA. HPV 18 was found in 61% of samples, with HPV 16 double-genotype in 6 patients (16%). Immunohistochemistry and qPCR data suggest that activation and expression of the EGFR signaling pathway is related to disease progression of conjunctival cancer. The associations between cytoplasmic p-MAPK, cytoplasmic p-Akt and tumor invasiveness were significant (p = 0.05 or 0.028). Nuclear p-EGFR appeared only in invasive tumors. A significant positive association between EGFR expression and disease invasiveness was observed (p = 0.01). A SNP in 10 patients and one missense mutation were found within EGFR tyrosine kinase domain. Statistical analysis indicates that patients with measurable EGFR expression more likely harbor EGFR mutations, compared to those with negative EGFR expression (35.3% vs. 0%). We conclude that HPV types 16/18 infection is frequent in East African patients with AIDS-associated squamous cell carcinoma of the conjunctiva. EGFR activation/alteration may contribute to and sustain the high prevalence of this cancer. Our findings hint that adoption of HPV vaccination strategies may impact the incidence of conjunctival carcinoma. Agents that target the EGFR pathway may have potential therapeutic benefit.
- 17 May 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (5) , e10477
Open AccessHPV Infection and EGFR Activation/Alteration in HIV-Infected East African Patients with Conjunctival Carcinoma
There has been substantial growth in the numbers of patients with conjunctival squamous cell carcinoma infected with HIV in East Africa. The natural history of the conjunctival squamous cell carcinoma appears to be unique in this region of the world, but the etiologic mechanism unclear and therapeutic options limited. This research was carried out to determine if conjunctival squamous cell carcinoma harbors human papillomavirus DNA and is associated with activation of the EGFR signaling pathway. Positive findings would identify etiologic causes and provide clinical guidance to improve treatment. Expression of p-MAPK/MAPK, p-Akt/Akt and p-EGFR/EGFR in cell nuclei and cytoplasm of 38 FFPE specimens were assessed by immunohistochemistry; HPV genotype was detected by qPCR assay; EGFR mutation was assessed by DNA sequencing analysis; and EGFR mRNA expression was measured using relative qPCR. Statistical analyses included two-sided Fisher exact test or chi-square test, Spearman correlation coefficient and ANOVA. HPV 18 was found in 61% of samples, with HPV 16 double-genotype in 6 patients (16%). Immunohistochemistry and qPCR data suggest that activation and expression of the EGFR signaling pathway is related to disease progression of conjunctival cancer. The associations between cytoplasmic p-MAPK, cytoplasmic p-Akt and tumor invasiveness were significant (p = 0.05 or 0.028). Nuclear p-EGFR appeared only in invasive tumors. A significant positive association between EGFR expression and disease invasiveness was observed (p = 0.01). A SNP in 10 patients and one missense mutation were found within EGFR tyrosine kinase domain. Statistical analysis indicates that patients with measurable EGFR expression more likely harbor EGFR mutations, compared to those with negative EGFR expression (35.3% vs. 0%). We conclude that HPV types 16/18 infection is frequent in East African patients with AIDS-associated squamous cell carcinoma of the conjunctiva. EGFR activation/alteration may contribute to and sustain the high prevalence of this cancer. Our findings hint that adoption of HPV vaccination strategies may impact the incidence of conjunctival carcinoma. Agents that target the EGFR pathway may have potential therapeutic benefit.
- 11 November 2009
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 1 (1) , 187-192
Gene expression patterns in the histopathological classification of epithelial ovarian cancer
The purpose of this study was to screen cancer-related genes and to identify histopathological gene expression patterns as potential biomarkers in human epithelial ovarian cancer (EOC). Fifty genes were screened by reverse-transcription polymerase chain reaction assay with cDNA from 83 EOC tissues and 48 normal ovarian specimens of ovarian cancer patients and evaluated by gel electrophoresis analysis. Twenty expressed genes were assessed by real-time relative-quantity (RQ)-PCR in 30 EOC specimens for gene signature study. Four genes, TAL2, EGF, ILF3 and UBE2I, were investigated for gene expression patterns in histopathological classification of EOC. RQ-value (Ct, ΔCt, ΔΔCt, RQ and gene expression plots) was generated by ABI 7500 Fast System SDS Software (version 1.4). SPSS 15.0 software was used for statistical analysis. Using real-time RQ-PCR, we found that TAL2, EGF, ILF3 and UBE2I demonstrated distinct expression patterns in histological types of epithelial ovarian cancer. The expression of ILF3 and UBE2I in tumors was significantly higher than in normal tissue, with extremely high expression in serous carcinomas compared to mucinous, endometrium and clear cell carcinomas. In addition, ILF3 and UBE2I were overexpressed in advanced stage and advanced grade ovarian cancer, compared to early stage or well-differentiated ovarian cancer. This is the first report of TAL2 and ILF3 expression in the normal human ovary and epithelial ovarian cancer. Our results indicate that overexpression of ILF3 and UBE2I in advanced stage and advanced grade suggest that these two genes may play an important role in tumorigenesis/tumor progression and pathological differentiation of the disease. Notably, ILF3 plays a role in DNA binding activity and transcriptional and post-transcriptional regulation; UBE2I is required in ubiquitination and sumoylation and is involved in DNA repair and apoptosis of cells. Further investigations to reveal the molecular mechanisms related to the activation of ILF3 and UBE2I in the development of EOC are warranted. Introduction Surface epithelial carcinomas are the most common type of ovarian cancer and the most lethal gynecological malignancy. Epithelial ovarian cancer (EOC) comprises the majority of malignant ovarian tumors in adult women, and its high mortality is mainly due to late diagnosis (1). Serous epithelial carcinoma, the primary type of ovarian cancer, usually presents at advanced stage. Endometrioid, mucinous and clear-cell carcinomas, accounting for non-serous carcinomas, more often appear as low-stage disease (1,2). In advanced stages, the response rate to first-line chemotherapy with a platinum combination after surgical resection is approximately 80%, with 40–60% complete response. However, the median progression-free survival is only 18 months in these patients, as most relapse. The overall response rate in platinum-refractory or drug-resistant tumors is only 10–25% with subsequent relapse, resulting in a 5-year survival of only 25% (3). In addition, clinicians have long known that different subtypes of ovarian cancer respond differently to treatment and have different prognoses. High-grade serous ovarian cancers typically harbor mutations in p53. These cancers also have mutations of BRCA1 or BRCA2, as well as defective homologous recombination, the preferred mechanism of the DNA double-strand break repair pathway (3,4). EOC, a morphologically and biologically heterogeneous disease, is affected by various gene activations and alterations (2–5). Current studies suggest that the different histological types of EOC represent distinct disease entities and exhibit varied gene expression patterns (6,7). Thus, a better understanding of the molecular basis of EOC subtypes and identification of a reliable gene expression profile for each type is necessary to uncover the fundamental mechanisms of carcinogenesis and to predict prognosis, and may provide therapeutic guidance in these diseases (8). DNA microarray research is widely applied in determining gene expression profiles and has opened the field for analysis of the expression levels of thousands of genes (9). However, a more accurate technique is needed for a better-tailored approach to identify special targets of diagnostic and prognostic markers that predict patient response to chemotherapy and survival outcomes. We used real-time relative-quantity (RQ)-PCR assay to illustrate a gene expression signature and to distinguish expression patterns in EOC subtypes in a large patient sample panel. Based on the function of targeted genes and their expression patterns, we identified ILF3 and UBE2I as potential biomarkers for this disease. Materials and methods Human tissue specimens Forty-eight pairs of ovarian specimens (tumor and adjacent normal tissues), plus an additional 35 tumors from a total of 83 patients with advanced ovarian cancer were obtained from the Cooperative Human Tissue Network (CHTN), Pediatric Division, Children's Hospital, Columbus, OH, USA. Tumor and normal samples were collected at primary surgery prior to chemotherapy, flash frozen in liquid nitrogen, and stored at −80°C until RNA/DNA extraction. All samples were evaluated by pathologists, and the 83 tumors were classified as serous carcinoma (n=51), endometrioid carcinoma (n=13), mucinous carcinoma (n=11) and clear cell carcinoma (n=8). RNA extraction Total RNA from each specimen and the normal control of the ovarian cancer patients was extracted and purified by the method of hot phenol/chloroform extraction as previously reported (10). Isolated RNA was purified and dissolved in DEPC water and stored at −80°C. Oligo synthesis Following a search of the gene database, we selected a total of 50 genes based on their functions and the expression literature in ovarian, breast and lung cancers for this investigation. Primary gene functions included transcription factor, DNA/RNA and protein binding activity, gene activation and regulation. Forward and reverse primers for each of the 50 genes were synthesized by Gene Probe Technologies, Inc. (Gaithersburg, MD, USA). Primer sequences of the 4 targeted genes used in real-time quantitative PCR assay are listed in Table I.Table I.Primer sequences of the 4 targeted genes used in real-time quantitative PCR.Table I.Primer sequences of the 4 targeted genes used in real-time quantitative PCR.Gene symbolGene IDForward primerReverse primerTAL26887 5′-tcaccctccagacaaaaagc-3′ 5′-ccaggtgaaggaacctggta-3′EGF1950 5′-aggtggctggaagcctttat-3′ 5′-tgtggacagaacctccatca-3′ILF33609 5′-ctggtgctgctgtgtaagga-3′ 5′-agggacaatggaggctcttt-3′UBE2I7329 5′-caggagaggaaagcatggag-3′ 5′-tcgggtgaaataatggtggt-3′ Reverse transcription-PCR Through reverse transcription (RT), using the Super Script Preamplification System (Life Technologies, Inc.), cDNA was generated with oligo-dT primers from 5 μg of total RNA of 83 ovarian tumor tissues and 48 adjacent normal samples. RT-PCR was performed using AmpliTaq DNA polymerase, FS cells and gene-specific primers of the 50 genes in all cDNA samples. PCR amplicons were separated by 1% agarose gel electrophoresis, and visible density bands of the gene amplification in these samples were indicative of gene expression. Genes expressed in RT-PCR detection were selected for subsequent real-time quantitative PCR analysis. Real-time quantitative PCR Real-time RQ-PCR was performed using SYBR® Green reagent kit (ABI Cat. 4367659) according to manufacturer's recommendations. This assay was used for 20 selected genes in 30 EOC specimens for the gene expression signature profile. Amplifications were carried out on ABI PRISM 7000 Detection System and analyzed by ABI 7500 software (PE Applied Biosystems, Foster City, CA, USA). In brief, all reactions were optimized to obtain the best amplification kinetics under the same cycling conditions (10 min at 95°C, 40 cycles of 15 sec at 95°C, and 1-min at 60°C). The composition of the reaction mixture in a final volume of 20 μl contained Power SYBR Green Master Mix 10 μl, gene-specific primers (10 μM) 1 μl and cDNA 2 μl. Negative controls containing all PCR components without template DNA (denoted NTC) were used to ensure that the reagent mix was free of contamination. Each reaction was run in triplicate. The average threshold cycle (Ct) and the comparative ΔΔCt method were automatically calculated for the expression of the gene and normalized to the mean Ct-value of 18S ribosomal. The RQ-value was calculated using the ΔΔCt method. Fold change in gene expression was calculated as 2−ΔΔCt. For each gene in this study, a Ct-value <32 was considered as positive expression and vice versa. Statistical analysis In real-time RQ-PCR assays, the average Ct, ΔCt, ΔΔCt and RQ were calculated by Applied Biosystems Sequence detection software (7500 Fast System SDS Software version 1.4). RQ (ΔΔCt value) was used to compare gene expression between samples. Since RQ equals 2−ΔΔCt, a higher negative ΔΔCt value, represents higher expression. SPSS 15.0 software was used to determine statistical significance. A P-value <0.05 was considered statistically significant between test means. Results Patient characteristics Forty-eight pairs of ovarian specimens (tumor and adjacent normal tissues) plus an additional 35 tumors (from a total of 83 ovarian cancer patients) were assessed in this investigation. The clinicopathological characteristics of the 83 EOC patients in this study are shown in Table II. The median age of the patients at diagnosis was 59 years (range, 37–83 years). Approximately 65.1% of the patients (54 out of 83) were diagnosed with advanced stage tumors (FIGO stages III/IV), and 84.3% (70 out of 83) had moderately poorly differentiated tumors (grades 2 and 3).Table II.Clinicopathological characteristics of the EOC cases.Table II.Clinicopathological characteristics of the EOC cases.Patient no.Age range (years)Histological typeFIGO stage at diagnosis Tumor grade IIIIIIIVG1G2G35140–83Serious3 (5.88%)2 (3.92%)42
- 11 November 2009
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 1 (1) , 187-192
Gene expression patterns in the histopathological classification of epithelial ovarian cancer
The purpose of this study was to screen cancer-related genes and to identify histopathological gene expression patterns as potential biomarkers in human epithelial ovarian cancer (EOC). Fifty genes were screened by reverse-transcription polymerase chain reaction assay with cDNA from 83 EOC tissues and 48 normal ovarian specimens of ovarian cancer patients and evaluated by gel electrophoresis analysis. Twenty expressed genes were assessed by real-time relative-quantity (RQ)-PCR in 30 EOC specimens for gene signature study. Four genes, TAL2, EGF, ILF3 and UBE2I, were investigated for gene expression patterns in histopathological classification of EOC. RQ-value (Ct, ΔCt, ΔΔCt, RQ and gene expression plots) was generated by ABI 7500 Fast System SDS Software (version 1.4). SPSS 15.0 software was used for statistical analysis. Using real-time RQ-PCR, we found that TAL2, EGF, ILF3 and UBE2I demonstrated distinct expression patterns in histological types of epithelial ovarian cancer. The expression of ILF3 and UBE2I in tumors was significantly higher than in normal tissue, with extremely high expression in serous carcinomas compared to mucinous, endometrium and clear cell carcinomas. In addition, ILF3 and UBE2I were overexpressed in advanced stage and advanced grade ovarian cancer, compared to early stage or well-differentiated ovarian cancer. This is the first report of TAL2 and ILF3 expression in the normal human ovary and epithelial ovarian cancer. Our results indicate that overexpression of ILF3 and UBE2I in advanced stage and advanced grade suggest that these two genes may play an important role in tumorigenesis/tumor progression and pathological differentiation of the disease. Notably, ILF3 plays a role in DNA binding activity and transcriptional and post-transcriptional regulation; UBE2I is required in ubiquitination and sumoylation and is involved in DNA repair and apoptosis of cells. Further investigations to reveal the molecular mechanisms related to the activation of ILF3 and UBE2I in the development of EOC are warranted. Introduction Surface epithelial carcinomas are the most common type of ovarian cancer and the most lethal gynecological malignancy. Epithelial ovarian cancer (EOC) comprises the majority of malignant ovarian tumors in adult women, and its high mortality is mainly due to late diagnosis (1). Serous epithelial carcinoma, the primary type of ovarian cancer, usually presents at advanced stage. Endometrioid, mucinous and clear-cell carcinomas, accounting for non-serous carcinomas, more often appear as low-stage disease (1,2). In advanced stages, the response rate to first-line chemotherapy with a platinum combination after surgical resection is approximately 80%, with 40–60% complete response. However, the median progression-free survival is only 18 months in these patients, as most relapse. The overall response rate in platinum-refractory or drug-resistant tumors is only 10–25% with subsequent relapse, resulting in a 5-year survival of only 25% (3). In addition, clinicians have long known that different subtypes of ovarian cancer respond differently to treatment and have different prognoses. High-grade serous ovarian cancers typically harbor mutations in p53. These cancers also have mutations of BRCA1 or BRCA2, as well as defective homologous recombination, the preferred mechanism of the DNA double-strand break repair pathway (3,4). EOC, a morphologically and biologically heterogeneous disease, is affected by various gene activations and alterations (2–5). Current studies suggest that the different histological types of EOC represent distinct disease entities and exhibit varied gene expression patterns (6,7). Thus, a better understanding of the molecular basis of EOC subtypes and identification of a reliable gene expression profile for each type is necessary to uncover the fundamental mechanisms of carcinogenesis and to predict prognosis, and may provide therapeutic guidance in these diseases (8). DNA microarray research is widely applied in determining gene expression profiles and has opened the field for analysis of the expression levels of thousands of genes (9). However, a more accurate technique is needed for a better-tailored approach to identify special targets of diagnostic and prognostic markers that predict patient response to chemotherapy and survival outcomes. We used real-time relative-quantity (RQ)-PCR assay to illustrate a gene expression signature and to distinguish expression patterns in EOC subtypes in a large patient sample panel. Based on the function of targeted genes and their expression patterns, we identified ILF3 and UBE2I as potential biomarkers for this disease. Materials and methods Human tissue specimens Forty-eight pairs of ovarian specimens (tumor and adjacent normal tissues), plus an additional 35 tumors from a total of 83 patients with advanced ovarian cancer were obtained from the Cooperative Human Tissue Network (CHTN), Pediatric Division, Children's Hospital, Columbus, OH, USA. Tumor and normal samples were collected at primary surgery prior to chemotherapy, flash frozen in liquid nitrogen, and stored at −80°C until RNA/DNA extraction. All samples were evaluated by pathologists, and the 83 tumors were classified as serous carcinoma (n=51), endometrioid carcinoma (n=13), mucinous carcinoma (n=11) and clear cell carcinoma (n=8). RNA extraction Total RNA from each specimen and the normal control of the ovarian cancer patients was extracted and purified by the method of hot phenol/chloroform extraction as previously reported (10). Isolated RNA was purified and dissolved in DEPC water and stored at −80°C. Oligo synthesis Following a search of the gene database, we selected a total of 50 genes based on their functions and the expression literature in ovarian, breast and lung cancers for this investigation. Primary gene functions included transcription factor, DNA/RNA and protein binding activity, gene activation and regulation. Forward and reverse primers for each of the 50 genes were synthesized by Gene Probe Technologies, Inc. (Gaithersburg, MD, USA). Primer sequences of the 4 targeted genes used in real-time quantitative PCR assay are listed in Table I.Table I.Primer sequences of the 4 targeted genes used in real-time quantitative PCR.Table I.Primer sequences of the 4 targeted genes used in real-time quantitative PCR.Gene symbolGene IDForward primerReverse primerTAL26887 5′-tcaccctccagacaaaaagc-3′ 5′-ccaggtgaaggaacctggta-3′EGF1950 5′-aggtggctggaagcctttat-3′ 5′-tgtggacagaacctccatca-3′ILF33609 5′-ctggtgctgctgtgtaagga-3′ 5′-agggacaatggaggctcttt-3′UBE2I7329 5′-caggagaggaaagcatggag-3′ 5′-tcgggtgaaataatggtggt-3′ Reverse transcription-PCR Through reverse transcription (RT), using the Super Script Preamplification System (Life Technologies, Inc.), cDNA was generated with oligo-dT primers from 5 μg of total RNA of 83 ovarian tumor tissues and 48 adjacent normal samples. RT-PCR was performed using AmpliTaq DNA polymerase, FS cells and gene-specific primers of the 50 genes in all cDNA samples. PCR amplicons were separated by 1% agarose gel electrophoresis, and visible density bands of the gene amplification in these samples were indicative of gene expression. Genes expressed in RT-PCR detection were selected for subsequent real-time quantitative PCR analysis. Real-time quantitative PCR Real-time RQ-PCR was performed using SYBR® Green reagent kit (ABI Cat. 4367659) according to manufacturer's recommendations. This assay was used for 20 selected genes in 30 EOC specimens for the gene expression signature profile. Amplifications were carried out on ABI PRISM 7000 Detection System and analyzed by ABI 7500 software (PE Applied Biosystems, Foster City, CA, USA). In brief, all reactions were optimized to obtain the best amplification kinetics under the same cycling conditions (10 min at 95°C, 40 cycles of 15 sec at 95°C, and 1-min at 60°C). The composition of the reaction mixture in a final volume of 20 μl contained Power SYBR Green Master Mix 10 μl, gene-specific primers (10 μM) 1 μl and cDNA 2 μl. Negative controls containing all PCR components without template DNA (denoted NTC) were used to ensure that the reagent mix was free of contamination. Each reaction was run in triplicate. The average threshold cycle (Ct) and the comparative ΔΔCt method were automatically calculated for the expression of the gene and normalized to the mean Ct-value of 18S ribosomal. The RQ-value was calculated using the ΔΔCt method. Fold change in gene expression was calculated as 2−ΔΔCt. For each gene in this study, a Ct-value <32 was considered as positive expression and vice versa. Statistical analysis In real-time RQ-PCR assays, the average Ct, ΔCt, ΔΔCt and RQ were calculated by Applied Biosystems Sequence detection software (7500 Fast System SDS Software version 1.4). RQ (ΔΔCt value) was used to compare gene expression between samples. Since RQ equals 2−ΔΔCt, a higher negative ΔΔCt value, represents higher expression. SPSS 15.0 software was used to determine statistical significance. A P-value <0.05 was considered statistically significant between test means. Results Patient characteristics Forty-eight pairs of ovarian specimens (tumor and adjacent normal tissues) plus an additional 35 tumors (from a total of 83 ovarian cancer patients) were assessed in this investigation. The clinicopathological characteristics of the 83 EOC patients in this study are shown in Table II. The median age of the patients at diagnosis was 59 years (range, 37–83 years). Approximately 65.1% of the patients (54 out of 83) were diagnosed with advanced stage tumors (FIGO stages III/IV), and 84.3% (70 out of 83) had moderately poorly differentiated tumors (grades 2 and 3).Table II.Clinicopathological characteristics of the EOC cases.Table II.Clinicopathological characteristics of the EOC cases.Patient no.Age range (years)Histological typeFIGO stage at diagnosis Tumor grade IIIIIIIVG1G2G35140–83Serious3 (5.88%)2 (3.92%)42
- 1 January 2009
- Published by Springer Nature
- p. 189-194
CHK2 and ERCC1 in the DNA Adduct Repair Pathway that Mediates Acquired Cisplatin Resistance
- 1 January 2009
- Published by Springer Nature
- p. 189-194
CHK2 and ERCC1 in the DNA Adduct Repair Pathway that Mediates Acquired Cisplatin Resistance